An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits

JJ Tu, E King, V Maksimova, S Smith, R Macias… - Journal of …, 2024 - Am Soc Microbiol
mRNA vaccine technology has proven to be a viable approach for effectively triggering
immune responses that protect against or limit viral infections and disease. In our study, we …

An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits

JJ Tu, E King, V Maksimova, S Smith… - Journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus responsible for adult T-cell
leukemia/lymphoma, a severe and fatal CD4+ T-cell malignancy. Additionally, HTLV-1 can …

An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.

JJ Tu, E King, V Maksimova, S Smith, R Macias… - Journal of …, 2024 - europepmc.org
IMPORTANCE mRNA vaccine technology has proven to be a viable approach for effectively
triggering immune responses that protect against or limit viral infections and disease. In our …

An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits

JJ Tu, E King, V Maksimova, S Smith… - Journal of …, 2024 - ohiostate.elsevierpure.com
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus responsible for adult T-cell
leukemia/lymphoma, a severe and fatal CD4+ T-cell malignancy. Additionally, HTLV-1 can …

An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.

JJ Tu, E King, V Maksimova, S Smith, R Macias… - Journal of …, 2024 - europepmc.org
mRNA vaccine technology has proven to be a viable approach for effectively triggering
immune responses that protect against or limit viral infections and disease. In our study, we …